QualityStocks'  Instablog

Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • Soligenix, Inc. (SNGX) Enters Into Commercial Collaboration With SciClone Pharmaceuticals In China For SGX942 0 comments
    Jul 9, 2013 11:25 AM | about stocks: SNGX

    Soligenix, a clinical-stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures, has established a personalized medicine collaboration with SciClone Pharmaceuticals in SNGX's oral mucositis clinical program with SGX942 for the treatment of oral mucositis (OM).

    Soligenix is developing SGX942 to address the unmet medical need of OM in solid tumor patients, especially those with head and neck cancer. OM affects approximately 90,000 head and neck cancer patients each year in the U.S. SGX942 recently received investigational new drug (NYSE:IND) clearance from the U.S. Food and Drug Administration (FDA) and is prepared to initiate a phase 2 clinical trial by year-end.

    The collaboration provides SNGX with access to SciClone's oral mucositis clinical and regulatory data library in exchange for commercialization rights in the People's Republic of China. According to SGNX CEO Christopher J. Schaber, PhD, this collaboration is the first time that a personalized medicine approach has been comprehensively integrated with an oral mucositis development program.

    "Our collaboration with SciClone is an ideal match," Dr. Schaber stated in the press release. "SciClone has a significant commercial presence and expertise in China, and their clinical and regulatory contribution to the SGX942 OM program has the potential to accelerate development while dramatically improving clinical response."

    SciClone completed two sequential phase 2 clinical studies in 2010 and 2012 evaluating its drug, SCV-07, for the treatment of OM caused by chemoradiation therapy in head and neck cancer patients, before terminating its program. Because SNGX is pursuing this same population for its OM program, the company believes this information has the potential to increase the probability of success of its upcoming phase 2 clinical study.

    For more information visit Soligenix.com

    Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net

    Stocks: SNGX
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.